Theragenics

Theragenics is a global specialty medical device company founded in 1981 by physicists from the Georgia Institute of Technology. The company focuses on developing radiological pharmaceuticals and devices to combat cancer. It is recognized for producing life-saving radioisotopes and brachytherapy seeds, particularly for prostate and localized cancers. Notable products include TheraSeed® and AgX100® implants, which are used worldwide to treat numerous patients. The company excels in radioisotope production, which supports its offerings in low-dose-rate (LDR) brachytherapy treatments. Theragenics has also expanded its product range to include medical devices for interventional radiology, interventional cardiology, vascular surgery, wound closure, and veterinary medicine. Additionally, it provides device design and development services, showcasing its commitment to advancing medical device innovation and enhancing patient outcomes. Theragenics collaborates with physicians, healthcare providers, and medical associations in over 40 countries, focusing on delivering effective treatments. Its products are trusted for their procedural and clinical outcomes, reflecting the company's mission to improve healthcare through innovative, patient-friendly technologies.

• Employees 190
• Founded 1981
• Annual Revenue $82559000
• Total Funding $40000000